SCYNEXIS, Inc. SCYX 深 滬
等待開盤 06-05 09:30:00 美东时间
4.90
+0.230
+4.93%
華盛通- 最 高5.1396
- 今 開4.70
- 成交量 6.94万股
- 最 低 4.70
- 昨 收 4.67
- 總市值 4865.86万
- 52周最高 10.48
- 市盈率 靜 --
- 換手率 0.70%
- 52周最低 4.52
- 委 比 -62.62%
- 總股本 993.03万
- 歷史最高 1200.00
- 量 比 0.29
- 振 幅 9.41%
- 歷史最低 4.52
- 每 手 1
- 風險率 1.07%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多AutoZone, Zscaler And 3 Stocks To Watch Heading Into Tuesday
U.S. stock futures are up, with investor focus on quarterly earnings from AutoZone, Elbit Systems, SCYNEXIS, Box, and Zscaler after the closing bell.
05-26 14:13
SCYNEXIS Announces 1-For-8 Reverse Stock Split, Effective May 29
SCYNEXIS, Inc. (NASDAQ:SCYX) ("SCYNEXIS"), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that it will effect a reverse stock split of its
05-23 04:16
SCYNEXIS Q1 EPS $(0.42) Misses $(0.12) Estimate
SCYNEXIS (NASDAQ:SCYX) reported quarterly losses of $(0.42) per share which missed the analyst consensus estimate of $(0.12) by 281.82 percent. This is a 281.82 percent decrease over losses of $(0.11) per share from the
05-12 04:34
SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SCYNEXIS, Inc. announced on May 6, 2026, that its Compensation Committee approved inducement equity awards for a new Vice President on April 30, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4). The awards include stock options for 125,000 shares with an exercise price of $0.93 and 20,000 RSUs, granted under the 2015 Inducement Award Plan. The stock options vest over four years, starting April 13, 2026, while the RSUs vest over three years...
05-07 01:15
SCYNEXIS Agrees With Poxel To Acquire PXL-770; $8M Upfront, Up To $188M Milestones
SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company focused on developing innovative new therapies to address severe rare diseases, today announced that it has entered into a definitive agreement with Poxel S.A.
03-31 18:43
SCYNEXIS Announces $40.0 Million Private Placement
SCYNEXIS, Inc. has entered into a private placement agreement with institutional and accredited investors, anticipate gross proceeds of approximately $40 million upfront, with an additional $52.2 million if Common Warrants are exercised, subject to stockholder approval. The company will issue 34.75 million common shares, 8.75 million pre-funded warrants, and 43.5 million common warrants. The financing includes participation from new and existing ...
03-31 10:45
SCYNEXIS Says On March 15, 2026 Co Received FDA Orphan Drug Designation For Brexafemme (Triterpenoid Antifungal) For Treatment Of Invasive Candidiasis
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1123525
03-17 00:18
SCYNEXIS Q4 Earnings Assessment
The Q4 earnings report for SCYNEXIS (NASDAQ:SCYX) was released on Wednesday, Ma...
03-05 05:48
SCYNEXIS Q4 EPS $0.25 Beats $0.13 Estimate, Sales $18.646M Beat $8.100M Estimate
SCYNEXIS (NASDAQ:SCYX) reported quarterly earnings of $0.25 per share which beat the analyst consensus estimate of $0.13 by 96.85 percent. This is a 377.78 percent increase over losses of $(0.09) per share from the same
03-05 05:40
